Home/Pipeline/Undisclosed Inhalation Program

Undisclosed Inhalation Program

Lung Cancer

Pre-clinicalActive

Key Facts

Indication

Lung Cancer

Phase

Pre-clinical

Status

Active

Company

InhaTarget Therapeutics

About InhaTarget Therapeutics

InhaTarget Therapeutics is an early-stage, private biotech company pioneering targeted inhalation therapies for severe respiratory conditions, starting with lung cancer. As a 2019 ULB spin-off, it leverages strong expertise in formulation, delivery, and clinical development to repurpose or improve existing molecules via inhalation. The company is currently in the preclinical/early clinical stage, actively presenting at major conferences and seeking validation for its platform. Its mission is to change the treatment paradigm by enhancing efficacy, stability, and patient convenience through localized pulmonary delivery.

View full company profile

Therapeutic Areas

Oncology Respiratory Diseases

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active